Inhibiting LSD1 with SP-2577 (Seclidemstat) induces ERV and IFNβ expression, promoting chemokine and PD-L1 upregulation, which enhances T-cell infiltration and tumor immunogenicity. Here, KDM1A is linked to neoplasm.